Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Chenfan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, 688 Yingbin Road, …. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, Jinhua Science and Technology Program Projects (Key).
Abstract (Originalsprache)
Androgen receptor (AR) antagonists play important roles in the treatment of castration-resistant prostate cancer (CRPC). The glucocorticoid receptor (GR) upregulation leads to drug resistance for clinically used antiandrogens. Therefore, blocking AR/GR signaling simultaneously has become an efficient strategy to overcome the drug resistance of CRPC. Our previous work indicated that Z19 could inhibit the activity of both AR and GR. Herein, we optimized the structure of Z19 and identified GA32 as a potent AR/GR dual inhibitor. GA32 efficiently reduced the mRNA and protein levels of AR/GR downstream genes. GA32 efficiently inhibited the proliferation of enzalutamide resistance CRPC both in vitro and in vivo. GA32 could directly bind to AR and GR, and the predicted binding modes for GA32 with AR/GR suggested that GA32 binds to the AR or GR hormone binding pocket. This work provides a potential lead compound with dual AR/GR inhibitory activity to conquer the drug resistance of CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, 688 Yingbin Road, Jinhua 321004, P. R. China.
- Department of Urology, Huizhou First People's Hospital, Huizhou, Guangdong 516003, P. R. China.
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P. R. China.
- Center for Drug Research and Evaluation, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, P. R. China.
ORCID-Profile: Jinming Zhou
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- Jinhua Science and Technology Program Projects (Key)
- China Health and Longevity Innovation Competition Funding
Zitieren
APA
Li, C., Han, X., Yan, Q., Ji, Y., Zhang, R., Yuan, D., Yang, F., Wang, J., Wu, M., & Zhou, J. (2024). Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01668
Vancouver
Li C, Han X, Yan Q, Ji Y, Zhang R, Yuan D, et al. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01668
BibTeX
@article{Li2024,
author = {Li, Chenfan and Han, Xiaoli and Yan, Qiuxia and Ji, Yang and Zhang, Rongyu and Yuan, Dazhong and Yang, Fulian and Wang, Jianlong and Wu, Meng and Zhou, Jinming},
title = {Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01668}
}
EUVIMED